Presented at the 55th annual meeting of the American Academy of Child and Adolescent Psychiatry, Chicago, IL, USA, October 28–November 2, 2008. Clinicaltrials.gov #NCT00232414
A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder
Article first published online: 10 JUL 2009
© 2009 The Authors. Journal compilation © 2009 John Wiley & Sons A/S
Volume 11, Issue 5, pages 483–493, August 2009
How to Cite
DelBello, M. P., Chang, K., Welge, J. A., Adler, C. M., Rana, M., Howe, M., Bryan, H., Vogel, D., Sampang, S., Delgado, S. V., Sorter, M. and Strakowski, S. M. (2009), A double-blind, placebo-controlled pilot study of quetiapine for depressed adolescents with bipolar disorder. Bipolar Disorders, 11: 483–493. doi: 10.1111/j.1399-5618.2009.00728.x
Disclosure information is listed before the references.
- Issue published online: 10 JUL 2009
- Article first published online: 10 JUL 2009
- Received 23 January 2009, revised and accepted for publication 3 April 2009
- bipolar disorder;
Objective: To conduct a pilot study comparing the effects of quetiapine and placebo for the treatment of depressive episodes in adolescents with bipolar I disorder.
Method: Thirty-two adolescents (ages 12–18 years) with a depressive episode associated with bipolar I disorder were randomized to eight weeks of double-blind treatment with quetiapine, 300–600 mg/day, or placebo. This two-site study was conducted from March 2006 through August 2007. The primary efficacy measure was change in Children’s Depression Rating Scale–Revised Version (CDRS-R) scores from baseline to endpoint. Secondary efficacy measures included change in CDRS-R scores over the eight-week study period (PROC MIXED), changes from baseline to endpoint in Hamilton Anxiety Rating Scale (HAM-A), Young Mania Rating Scale (YMRS), and Clinical Global Impression–Bipolar Version Severity (CGI-BP-S) scores, as well as response and remission rates. Safety and tolerability were assessed weekly.
Results: There was no statistically significant treatment group difference in change in CDRS-R scores from baseline to endpoint (p = 0.89, effect size =−0.05, 95% confidence interval: −0.77–0.68), nor in the average rate of change over the eight weeks of the study (p = 0.95). Additionally, there were no statistically significant differences in response (placebo =67% versus quetiapine = 71%) or remission (placebo = 40% versus quetiapine = 35%) rates, or change in HAM-A, YMRS, or CGI-BP-S scores (all p > 0.7) between treatment groups. Dizziness was more commonly reported in the quetiapine (41%) than in the placebo (7%) group (Fisher’s exact test, p = 0.04).
Conclusions: The results suggest that quetiapine monotherapy is no more effective than placebo for the treatment of depression in adolescents with bipolar disorder. However, limitations of the study, including the high placebo response rate, may have contributed to our findings and should be considered in the design of future investigations of pharmacological interventions for this population.